A new personalized mRNA vaccine for pancreatic cancer is showing encouraging results in early clinical trials, offering hope against this highly lethal disease. The vaccine trains the immune system to recognize tumor-specific mutations, activating long-lasting T cells that persisted for nearly four years and reduced recurrence rates in responding patients, even during chemotherapy.
Each vaccine is tailored to the individual: scientists sequence a patient’s tumor DNA, identify mutations likely to trigger immunity, and create a custom mRNA vaccine targeting those markers. In a small trial at Memorial Sloan Kettering, 16 patients received the vaccine, and half developed strong immune responses. Among these responders, six remained cancer-free, with T cells projected to remain active for years or even decades.
Given that pancreatic cancer has only a 13% five-year survival rate, this personalized mRNA vaccine could represent a major breakthrough, potentially transforming treatment for one of the deadliest cancers.